Tags : Rituxan

Top 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More


Chugai’s Rozlytrek Receives MHLW’s Approval for ROS1 Fusion-Positive Non-Small Cell

Shots: The approval is based on P-II STARTRK-2 study assessing the efficacy of Rozyltrek in ROS1 fusion-positive NSCLC cohort while the safety is evaluated in two P-I studies (STARTRK-1 study and ALKA-372-001 study) Additionally, Chugai receives MHLW’s approval for Alecensa (alectinib hydrochloride) and Rituxan to treat r/r ALK-positive ALCL) and ATTP respectively Rozlytrek is an […]Read More

Biotech Regulatory

Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan)

Shots: Teva and Celltrion launch Truxima (rituximab-abbs) injection as the first biosimilar referencing Roche’s Rituxan (rituximab) to be available in the US by the week of November 11, addressing the unmet medical needs of the patients in the US The approval of Truxima is based on clinical/ nonclinical, pharmacology, immunogenicity, clinical efficacy and safety data. […]Read More


Roche’s Rituxan (rituximab) Receives the US FDA’s Approval for Two

Shots: The FDA’s approval is based on P-IIa PePRS study assessing MabThera/Rituxan (IV) + glucocorticoids in 25 pediatric patients with active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) aged 6-17yrs. The P-IIa PePRS study results: the achievement of PVAS remission @6mos. (56%); @12mos. (92%); @18mos. (100%); safety profile in pediatric patients with GPA & […]Read More